Evidence map›Paper›PMID 25104273›Full record

Trial reportClinical journal of the American Society of Nephrology : CJASN2014

Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial.

Ellen K Hoogeveen, Johanna M Geleijnse, Daan Kromhout, Theo Stijnen, Eugenie F Gemen, Ron Kusters, Erik J Giltay

2 registry-linked trialsOpen access · bronzeAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 35 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 10 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03192410 active not recruitingnot on this map

Prospective Cohort Study of 4,837 Post-myocardial Infarction Patients (Alpha Omega Cohort)

TypeobservationalSponsorWageningen UniversityRan2002 to 2040Enrolled4,837ConditionsCardiovascular Diseases, Mortality, Type 2 Diabetes Mellitus, Cognitive DeclineArmsDietary intake, Lifestyle factors, Blood biomarkers, Health, DNA
NCT03280615 phase3completednot on this mapstarted 2017, after this paper: background citation

Effects of the Supplementation With Omega 3 Fatty Acids in Patients With Chronic Renal Disease

TypeinterventionalSponsorUniversity of ChileRan2017 to 2018Enrolled100ConditionsRenal Insufficiency, ChronicArmsOmega 3 fatty acids, Corn oil
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 10 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Marine-derived n-3 fatty acids therapy for stroke.The Cochrane database of systematic reviews · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Marine-derived n-3 fatty acids therapy for stroke.The Cochrane database of systematic reviews · 2019
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ellen K HoogeveenDepartments of Internal Medicine and Nephrology and ellen.hoogeveen@planet.nl.
Johanna M GeleijnseDivision of Human Nutrition, Wageningen University, Wageningen, The Netherlands; and.
Daan KromhoutDivision of Human Nutrition, Wageningen University, Wageningen, The Netherlands; and.
Theo StijnenDepartments of Medical Statistics and Bioinformatics and.
Eugenie F GemenClinical Chemistry, Jeroen Bosch Hospital, Den Bosch, The Netherlands;
Ron KustersClinical Chemistry, Jeroen Bosch Hospital, Den Bosch, The Netherlands;
Erik J GiltayPsychiatry, Leiden University Medical Center, Leiden, The Netherlands.
Jeroen Bosch Ziekenhuis · NLWageningen University & Research · NLLeiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesKidney function gradually decreases with age, and myocardial infarction accelerates this deterioration. Omega-3 (n-3) fatty acids may slow down the decline of kidney function. The effect of marine and plant-derived n-3 fatty acids on kidney function in patients after myocardial infarction was examined. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In the Alpha Omega Trial, 2344 patients with history of myocardial infarction ages 60-80 years old (81% men) were randomized to one of four trial margarines. The patients received an additional targeted amount of 400 mg/d eicosapentaenoic acid and docosahexaenoic acid, 2 g/d α-linolenic acid, eicosapentaenoic acid-docosahexaenoic acid plus α-linolenic acid, or placebo for 40 months. Serum cystatin C and serum creatinine were assessed at baseline and after 40 months. Creatinine-cystatin C-based GFR was estimated with the Chronic Kidney Disease Epidemiology Collaboration equation.

resultsPatients consumed 19.9 g margarine/d, providing an additional 239 mg/d eicosapentaenoic acid with 159 mg/d docosahexaenoic acid, 1.99 g/d α-linolenic acid, or both in the active treatment groups. After 40 months, compared with baseline, mean (±SD) creatinine-cystatin C-based GFR was -6.9 (±12.6), -4.8 (±13.4), -6.2 (±12.8), and -6.0 (±13.0) ml/min per 1.73 m(2) in the placebo, eicosapentaenoic acid-docosahexaenoic acid, α-linolenic acid, and eicosapentaenoic acid-docosahexaenoic acid plus α-linolenic acid groups, respectively. After 40 months, in patients receiving eicosapentaenoic acid-docosahexaenoic acid compared with placebo, the decline in creatinine-cystatin C-based GFR was 2.1 less (95% confidence interval, 0.6 to 3.6; P<0.01) ml/min per 1.73 m(2); other comparisons were not statistical significant. Odds ratios (95% confidence intervals) of incident CKD (<60 ml/min per 1.73 m(2)) and rapid decline of kidney function (≥3 ml/min per year) for eicosapentaenoic acid-docosahexaenoic acid compared with placebo were 0.83 (0.58 to 1.18) and 0.85 (0.67 to 1.08), respectively.

conclusionsLong-term supplementation with 400 mg/d eicosapentaenoic acid-docosahexaenoic acid provides a small beneficial effect on kidney function in patients with a history of myocardial infarction.

Indexed as

Food, FortifiedGlomerular Filtration RateMargarineAgedAged, 80 and overalpha-Linolenic AcidBiomarkersChi-Square DistributionCreatinineCystatin CDisease ProgressionDocosahexaenoic AcidsDouble-Blind MethodEicosapentaenoic AcidFemaleHumansalpha-Linolenic AcidBiomarkersCreatinineCST3 protein, humanCystatin CDocosahexaenoic AcidsEicosapentaenoic AcidMargarinecardiovascular diseaseCKDclinical trialnutritionomega-3 fatty acids

Identifiers

PMID25104273
PMCPMC4186521
OpenAlexW2166905156

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.